Key Details
Price
$3.63Annual EPS
-$3.95Annual ROE
-84.27%Beta
0.50Events Calendar
Next earnings date:
Mar 26, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Feb 13, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle
After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024.
DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor.
Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.87 per share a year ago.
Aprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
FAQ
- What is the primary business of Aprea Therapeutics?
- What is the ticker symbol for Aprea Therapeutics?
- Does Aprea Therapeutics pay dividends?
- What sector is Aprea Therapeutics in?
- What industry is Aprea Therapeutics in?
- What country is Aprea Therapeutics based in?
- When did Aprea Therapeutics go public?
- Is Aprea Therapeutics in the S&P 500?
- Is Aprea Therapeutics in the NASDAQ 100?
- Is Aprea Therapeutics in the Dow Jones?
- When was Aprea Therapeutics's last earnings report?
- When does Aprea Therapeutics report earnings?
- Should I buy Aprea Therapeutics stock now?